MEAGAN CAPUCHINO: Open Payments
NPI 1346940624 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$252 in 13 payments from 9 companies in 2025. Trend: 2023 $312 · 2024 $346 · 2025 $252
Food & beverage: $252
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 2 | $45 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $43 |
| AstraZeneca Pharmaceuticals LP | 2 | $39 |
| Amgen Inc. | 2 | $28 |
| PFIZER INC. | 1 | $22 |
| Lilly USA, LLC | 1 | $22 |
| ABBVIE INC. | 1 | $19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $18 |
| Novo Nordisk Inc | 1 | $15 |
Products named: Kerendia, JARDIANCE, AIRSUPRA, TRELEGY ELLIPTA, PREVNAR 20, QULIPTA, SHINGRIX, Rybelsus.
Industry payments across TX — which companies pay providers there.
